RankAlpha logo
Back to Rankings

RFL

RafaelB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The bull case is that RFL now looks increasingly like a focused Trappsol Cyclo vehicle, with management explicitly prioritizing completion of the pivotal Phase 3 trial and an April 2026 MIT license that may support follow-on neurodegenerative optionality [#10-Q-2026-03-16][#8-K-2026-04-22].
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-11-02.
What can break
Cash burn and clinical spending trends may force additional financing before full de-risking of the lead program.
Momentum
66
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.20 · Bull $2.10 · Bear $0.70Analysis 2026-05-07; returns require an exact persisted reference.
Earnings
2026-11-02
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-28

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Why
Momentum66 · Δ7d -
Value41 · Δ7d -0.1
Sentiment74 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-11-02.
  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • Cash burn and clinical spending trends may force additional financing before full de-risking of the lead program.
  • • The MIT Alzheimer license may remain early-stage optionality unless Rafael discloses a funded development path, economics, or regulatory timeline.
  • • The bear case is that conviction still rests on one major readout, while cash declined to $37.8 million at January 31, 2026 and six-month operating cash burn accelerated, leaving financing and dilution risk meaningful if timelines slip or data disappoint [#10-Q-2026-03-16].

Catalyst clock

2026-11-02

Runway and financing scrutiny should rise as trial spend continues

Lead driver: Sentiment · See AI snapshot
Momentum
66
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
74
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 65.6 / Value 40.6 / Sentiment 74.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-07. Scenario method

B+
Bull case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-05-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$58.25M
Beta
0.68
Shares Out
52M
P/E (TTM) · Derived
-1.9
P/S (TTM)
63.89
P/FCF (TTM) · Derived
-1.69
Rev YoY
-50.6%
EPS YoY
-55.8%
Gross Margin
+74.4%
Op Margin
-3717.2%
Net Debt
-$52.08M
Current Ratio
3.16
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data